These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 35129198)

  • 1. Emergent players in renovascular disease.
    Barsom SH; Glasstetter LM; Siddiqi S; Rajagopalan KS; Eirin A; Lerman LO
    Clin Sci (Lond); 2022 Feb; 136(3):239-256. PubMed ID: 35129198
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kidney Intrinsic Mechanisms as Novel Targets in Renovascular Hypertension.
    Eirin A; Chade AR; Lerman LO
    Hypertension; 2024 Feb; 81(2):206-217. PubMed ID: 37869904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel therapeutic strategies for renovascular disease.
    Eirin A; Textor SC; Lerman LO
    Curr Opin Nephrol Hypertens; 2019 Jul; 28(4):383-389. PubMed ID: 31045658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesenchymal Stem Cell-Derived Extracellular Vesicles Improve the Renal Microvasculature in Metabolic Renovascular Disease in Swine.
    Eirin A; Zhu XY; Jonnada S; Lerman A; van Wijnen AJ; Lerman LO
    Cell Transplant; 2018 Jul; 27(7):1080-1095. PubMed ID: 29954220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesenchymal Stem/Stromal Cell-Derived Extracellular Vesicles Elicit Better Preservation of the Intra-Renal Microvasculature Than Renal Revascularization in Pigs with Renovascular Disease.
    Ferguson CM; Farahani RA; Zhu XY; Tang H; Jordan KL; Saadiq IM; Lerman A; Lerman LO; Eirin A
    Cells; 2021 Mar; 10(4):. PubMed ID: 33807246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coexisting renal artery stenosis and metabolic syndrome magnifies mitochondrial damage, aggravating poststenotic kidney injury in pigs.
    Nargesi AA; Zhang L; Tang H; Jordan KL; Saadiq IM; Textor SC; Lerman LO; Eirin A
    J Hypertens; 2019 Oct; 37(10):2061-2073. PubMed ID: 31465309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelin-A receptor blockade slows the progression of renal injury in experimental renovascular disease.
    Kelsen S; Hall JE; Chade AR
    Am J Physiol Renal Physiol; 2011 Jul; 301(1):F218-25. PubMed ID: 21478482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathogenesis and management of renovascular hypertension and ischemic nephropathy.
    Yerram P; Karuparthi PR; Chaudhary K
    Minerva Urol Nefrol; 2012 Mar; 64(1):63-72. PubMed ID: 22402318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of acute and chronic antioxidant interventions in experimental renovascular disease.
    Chade AR; Krier JD; Rodriguez-Porcel M; Breen JF; McKusick MA; Lerman A; Lerman LO
    Am J Physiol Renal Physiol; 2004 Jun; 286(6):F1079-86. PubMed ID: 14722019
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antioxidant intervention blunts renal injury in experimental renovascular disease.
    Chade AR; Rodriguez-Porcel M; Herrmann J; Zhu X; Grande JP; Napoli C; Lerman A; Lerman LO
    J Am Soc Nephrol; 2004 Apr; 15(4):958-66. PubMed ID: 15034098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endovascular management of atherosclerotic renovascular disease: early results following primary intervention.
    Corriere MA; Pearce JD; Edwards MS; Stafford JM; Hansen KJ
    J Vasc Surg; 2008 Sep; 48(3):580-7; discussion 587-8. PubMed ID: 18727962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percutaneous revascularization for ischemic nephropathy: the past, present, and future.
    Textor SC; Misra S; Oderich GS
    Kidney Int; 2013 Jan; 83(1):28-40. PubMed ID: 23151953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ischemic nephropathy: more than a simple renal artery narrowing.
    Khatami MR
    Iran J Kidney Dis; 2013 Mar; 7(2):82-100. PubMed ID: 23485531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endothelin-a receptor antagonism after renal angioplasty enhances renal recovery in renovascular disease.
    Chade AR; Tullos N; Stewart NJ; Surles B
    J Am Soc Nephrol; 2015 May; 26(5):1071-80. PubMed ID: 25377076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Atherosclerotic renovascular disease and renal function].
    Halimi JM; Mimran A
    Rev Prat; 1995 Oct; 45(16):1998-2001. PubMed ID: 8578109
    [No Abstract]   [Full Text] [Related]  

  • 16. Selective improvement in renal function preserved remote myocardial microvascular integrity and architecture in experimental renovascular disease.
    Urbieta-Caceres VH; Zhu XY; Jordan KL; Tang H; Textor K; Lerman A; Lerman LO
    Atherosclerosis; 2012 Apr; 221(2):350-8. PubMed ID: 22341593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic blockade of endothelin A and B receptors using macitentan in experimental renovascular disease.
    Tullos NA; Stewart NJ; Davidovich R; Chade AR
    Nephrol Dial Transplant; 2015 Apr; 30(4):584-93. PubMed ID: 25438341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. With a Little Help From My Friends: the Role of the Renal Collateral Circulation in Atherosclerotic Renovascular Disease.
    Nyvad J; Lerman A; Lerman LO
    Hypertension; 2022 Apr; 79(4):717-725. PubMed ID: 35135307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disparate effects of single endothelin-A and -B receptor blocker therapy on the progression of renal injury in advanced renovascular disease.
    Chade AR; Stewart NJ; Peavy PR
    Kidney Int; 2014 Apr; 85(4):833-44. PubMed ID: 24352153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renovascular hypertension.
    Bruni KR
    J Cardiovasc Nurs; 2001 Jul; 15(4):78-90. PubMed ID: 11419667
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.